Aldi Recall Alert: Hidden Allergens in Two Products Sold in 16 States
The first recall involves Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. According to the U.S. Food and Drug Administration, the product may contain undeclared milk, a major allergen.
The affected churro bites come in 7.05-ounce cardboard boxes marked with UPC Code 4061459561807 and a "Best If Used By" date of July 14, 2026. While no illnesses have been reported, customers with milk allergies are advised not to consume the product and instead return it to Aldi for a full refund.
This product was distributed in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee.
The second recall affects Atlantic Salmon Portions with Seafood Stuffing, manufactured by Santa Monica Seafood. This item was sold in 16-ounce packages with UPC Code 4061459716313 and a use/freeze-by date of June 2, 2025. It was distributed to Aldi locations in California, Nevada, and Arizona. The product may contain undeclared soy, another top allergen that can cause serious reactions for sensitive individuals.
For customers with food allergies, these undeclared ingredients pose a serious health risk. Dr. Sebastian Lighvani, a New York-based allergist, explained to Newsweek that even trace amounts of allergens like milk or soy can trigger immune responses in susceptible individuals. They could lead to potentially life-threatening reactions.
Aldi emphasized its commitment to consumer safety in a statement, directing concerned customers to their recall page and offering full refunds on returned products.
Whether you have known allergies or not, it's worth taking a moment to check your fridge and freezer. Recalls like these are a reminder of how vital food labeling and consumer awareness are, especially when it comes to the ingredients we can't see.
Aldi Recall Alert: Hidden Allergens in Two Products Sold in 16 States first appeared on Men's Journal on Jun 11, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
43 minutes ago
- Business Wire
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include patents relating to its use in a long-acting HIV treatment regimen. The announcement follows updated guidance from WHO recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing generic licensees for prevention will be able to develop, manufacture and supply generic CAB LA, for use in combination with long-acting rilpivirine, subject to required regulatory approvals being obtained, to help enable access to the long-acting treatment in 133 countries worldwide. This includes all least-developed, low-income, lower middle-income and Sub-Saharan African countries, as well as countries where ViiV does not have patent rights for cabotegravir. Deborah Waterhouse, CEO at ViiV Healthcare said: 'As leaders in long-acting innovation we're proud to be expanding our voluntary licence with the MPP to now include treatment of HIV in addition to prevention. Long-acting injectables have the potential to transform HIV treatment and we welcome the latest recommendations from WHO to expand treatment options. In line with our mission to ensure no one living with HIV is left behind, we're committed to working with partners like MPP to continue to increase access and reach those most impacted by HIV.' Charles Gore, Executive Director at MPP said: 'We're delighted to extend the CAB LA licence to cover HIV treatment, reflecting the latest WHO recommendations. Our previous agreement with ViiV for dolutegravir has already enabled the supply of generic DTG-based HIV treatments in 129 countries and we hope that over time a similar coverage can be achieved for CAB LA. CAB LA is a vital addition to the HIV treatment toolbox — especially for people facing adherence challenges with oral regimens. Expanding access to long-acting options like this supports a more person-centred, choice- and needs-driven approach, which is exactly what an equitable and effective HIV response requires.' Dr Meg Doherty, Director Global HIV, Hepatitis and STI Programmes said:"The World Health Organization welcomes the expansion of the voluntary licence agreement for long-acting cabotegravir to include HIV treatment. This step is closely aligned with WHO's new recommendation of long-acting injectable antiretrovirals as an alternative for people who are virologically suppressed but face adherence challenges with daily oral regimens. It reflects our commitment to expanding access to innovative, person-centered treatment options that improve outcomes — particularly in underserved regions. This agreement aligns with our global goals to ensure equitable access to essential medicines and improve health outcomes for all. We are committed to supporting countries in implementing these new guidelines and ensuring that no one is left behind.' The updated MPP-ViiV agreement is an extension of the voluntary license for cabotegravir for HIV PrEP. ViiV Healthcare has been supporting the generic manufacturers with technical know-how to enable development and access to CAB LA as soon as possible. Through the agreement, the existing licensees, Aurobindo, Cipla and Viatris, will be able to develop, manufacture and supply generic versions of CAB LA, for use in combination with long-acting rilpivirine, for the treatment of HIV-1 infection in adults and adolescents weighing at least 35kg, subject to required regulatory approvals being obtained. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About Apretude (cabotegravir long-acting) Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir. Please consult the full EU Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection About Vocabria (cabotegravir) Vocabria injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents (at least 12 years of age and weighing at least 35kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class. Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for: oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection. oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection. Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant (rilpivirine) tablets should also be consulted for recommended dosing. Please consult the full EU Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets About Rekambys (rilpivirine) Rekambys is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35kg) who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class. Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing. Rekambys may be initiated with oral lead-in or without (direct to injection). Please consult the full EU Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at About MPP The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies. MPP was founded by Unitaid, which continues to be MPP's main funder. MPP's work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP's activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
Yahoo
an hour ago
- Yahoo
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
Both Tru Niagen, featured as the newest in-room offering for hotel guests, and Niagen IV, available at NutriDrip's location at The Spa by Equinox Hotel New York, support cellular energy production and DNA repair for optimal recovery LOS ANGELES, July 14, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel's spa through NutriDrip. Rob Fried, CEO of Niagen Bioscience, remarked, "Our partnership with Equinox Hotel and NutriDrip underscores our commitment to growing consumer access, driving brand strength, and capturing new market opportunities for our flagship Niagen products." Equinox Hotels, a luxury hospitality brand built on the evolution of Equinox, has been thoroughly conceptualized and brought to life to translate a high-performance lifestyle into a seamless guest experience through cutting-edge and science-backed fitness, recovery, and nutrition services. Hotel guests can now experience the transformative cellular health benefits of Tru Niagen, the number one healthy-aging NAD+ supplement in the United States†, with bottles available as the newest in-room offering. Additionally, the groundbreaking pharmaceutical-grade product, Niagen IV, is available at The Spa by Equinox Hotel New York through NutriDrip. Angela Portella, Director of Spa at Equinox Hotel, commented, "At Equinox Hotels, we provide our community with the highest quality, science-backed products and services. Tru Niagen, recognized as the gold-standard NAD+-boosting supplement, and NutriDrip, the best in the IV therapy business, reflect our mission." Tru Niagen and Niagen IV are powered by Niagen Bioscience's clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside or NR), the most efficient, well-researched, and high-quality NAD+ booster available. NAD+ is a vital coenzyme found in every cell of the human body that supports cellular energy production and DNA repair to support recovery. Asa Kitfield, Managing Partner at Clean Market & NutriDrip, remarked, "We are thrilled to offer Niagen IV at our premium Equinox Hotel New York location. This cutting-edge infusion represents a profound advancement for elevating NAD+ intravenously. It's a game-changer for muscle health and recovery." About Tru Niagen and Niagen IV Tru Niagen is backed by the highest scientific and quality standards, including a Nobel Prize winner, 35+ human clinical studies, 400+ published scientific studies, and has been accepted by the world's most rigorous regulatory bodies. All Tru Niagen products are third-party certified, with Tru Niagen Pro 1,000mg and Tru Niagen Stick Packs NSF Certified for Sport, ensuring their safety, quality, and integrity for elite athletes and fitness enthusiasts alike. Niagen IV represents a significant advancement in intravenous NAD+-boosting therapy. NAD+ IV has gained popularity amongst doctors, fitness experts, celebrities, and athletes because of the substantial benefits, but the experience can be unpleasant. In a head-to-head comparison with NAD+ IV, Niagen IV offered superior tolerability, a 75% shorter infusion time, and resulted in a statistically significant 20% increase in whole blood NAD+ levels three hours post-infusion (MedRxiv). For additional information on the science supporting Niagen, visit Learn more about Equinox Hotel New York at and NutriDrip at About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). About Equinox Hotels Equinox Hotels is a rapidly expanding, global luxury hospitality brand and management company built off the evolution of Equinox. With a design-forward perspective and 360-approach to luxury lifestyle, our portfolio spans urban, resort, and destination locations globally set in architecturally stunning spaces built for high-performance living. Only Equinox Hotels can seamlessly integrate a hotel experience with an existing community of engaged, loyal members who activate the Clubs daily. Equinox Branded Residences offer lifestyle, status, and the notion of health associated with the Equinox brand and global membership. Equinox Hotels has a robust global pipeline that is defining a new category of luxury. For more information on Equinox Hotels please visit: About NutriDrip As a leader in functional wellness, NutriDrip provides IV Nutrient Therapy for therapeutic and rejuvenating benefits with a full menu of signature Wellness and Recovery IV Drips. Traditional oral supplementation is hard for your body to absorb and results are slow, while IV Nutrient Therapy provides 100% bioavailability for fast-acting results. NutriDrip's signature IV Drips, which are administered by nurse practitioners and registered nurses, utilize fluids, electrolytes, vitamins and minerals to help you feel & function better. Knowing that we all have different health and nutritional needs, NutriDrip takes a personalized approach to wellness with a best-in-class medical team that will help select and customize the right IV Drip protocol for you. Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: ICR, LLCReed Anderson(646) 277-1260Stephanie Carrington(646) 277-1282niagenir@ Equinox Hotels Media Contact: Caroline McKayCaroline@
Yahoo
2 hours ago
- Yahoo
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
Both Tru Niagen, featured as the newest in-room offering for hotel guests, and Niagen IV, available at NutriDrip's location at The Spa by Equinox Hotel New York, support cellular energy production and DNA repair for optimal recovery LOS ANGELES, July 14, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel's spa through NutriDrip. Rob Fried, CEO of Niagen Bioscience, remarked, "Our partnership with Equinox Hotel and NutriDrip underscores our commitment to growing consumer access, driving brand strength, and capturing new market opportunities for our flagship Niagen products." Equinox Hotels, a luxury hospitality brand built on the evolution of Equinox, has been thoroughly conceptualized and brought to life to translate a high-performance lifestyle into a seamless guest experience through cutting-edge and science-backed fitness, recovery, and nutrition services. Hotel guests can now experience the transformative cellular health benefits of Tru Niagen, the number one healthy-aging NAD+ supplement in the United States†, with bottles available as the newest in-room offering. Additionally, the groundbreaking pharmaceutical-grade product, Niagen IV, is available at The Spa by Equinox Hotel New York through NutriDrip. Angela Portella, Director of Spa at Equinox Hotel, commented, "At Equinox Hotels, we provide our community with the highest quality, science-backed products and services. Tru Niagen, recognized as the gold-standard NAD+-boosting supplement, and NutriDrip, the best in the IV therapy business, reflect our mission." Tru Niagen and Niagen IV are powered by Niagen Bioscience's clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside or NR), the most efficient, well-researched, and high-quality NAD+ booster available. NAD+ is a vital coenzyme found in every cell of the human body that supports cellular energy production and DNA repair to support recovery. Asa Kitfield, Managing Partner at Clean Market & NutriDrip, remarked, "We are thrilled to offer Niagen IV at our premium Equinox Hotel New York location. This cutting-edge infusion represents a profound advancement for elevating NAD+ intravenously. It's a game-changer for muscle health and recovery." About Tru Niagen and Niagen IV Tru Niagen is backed by the highest scientific and quality standards, including a Nobel Prize winner, 35+ human clinical studies, 400+ published scientific studies, and has been accepted by the world's most rigorous regulatory bodies. All Tru Niagen products are third-party certified, with Tru Niagen Pro 1,000mg and Tru Niagen Stick Packs NSF Certified for Sport, ensuring their safety, quality, and integrity for elite athletes and fitness enthusiasts alike. Niagen IV represents a significant advancement in intravenous NAD+-boosting therapy. NAD+ IV has gained popularity amongst doctors, fitness experts, celebrities, and athletes because of the substantial benefits, but the experience can be unpleasant. In a head-to-head comparison with NAD+ IV, Niagen IV offered superior tolerability, a 75% shorter infusion time, and resulted in a statistically significant 20% increase in whole blood NAD+ levels three hours post-infusion (MedRxiv). For additional information on the science supporting Niagen, visit Learn more about Equinox Hotel New York at and NutriDrip at About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). About Equinox Hotels Equinox Hotels is a rapidly expanding, global luxury hospitality brand and management company built off the evolution of Equinox. With a design-forward perspective and 360-approach to luxury lifestyle, our portfolio spans urban, resort, and destination locations globally set in architecturally stunning spaces built for high-performance living. Only Equinox Hotels can seamlessly integrate a hotel experience with an existing community of engaged, loyal members who activate the Clubs daily. Equinox Branded Residences offer lifestyle, status, and the notion of health associated with the Equinox brand and global membership. Equinox Hotels has a robust global pipeline that is defining a new category of luxury. For more information on Equinox Hotels please visit: About NutriDrip As a leader in functional wellness, NutriDrip provides IV Nutrient Therapy for therapeutic and rejuvenating benefits with a full menu of signature Wellness and Recovery IV Drips. Traditional oral supplementation is hard for your body to absorb and results are slow, while IV Nutrient Therapy provides 100% bioavailability for fast-acting results. NutriDrip's signature IV Drips, which are administered by nurse practitioners and registered nurses, utilize fluids, electrolytes, vitamins and minerals to help you feel & function better. Knowing that we all have different health and nutritional needs, NutriDrip takes a personalized approach to wellness with a best-in-class medical team that will help select and customize the right IV Drip protocol for you. Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: ICR, LLCReed Anderson(646) 277-1260Stephanie Carrington(646) 277-1282niagenir@ Equinox Hotels Media Contact: Caroline McKayCaroline@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
